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OBJECTIVES We sought to compare survival after coronary artery bypass graft (CABG) and percutaneous
transluminal coronary angioplasty (PTCA) in high-risk anatomic subsets.
BACKGROUND Compared with medical therapy, CABG decreases mortality in patients with three-vessel
disease and two-vessel disease involving the proximal left anterior descending artery (LAD),
particularly if left ventricular (LV) dysfunction is present. How survival after PTCA and
CABG compares in these high-risk anatomic subsets is unknown.
METHODS In the Bypass Angioplasty Revascularization Investigation (BARI), 1,829 patients with
multivessel disease were randomized to an initial strategy of PTCA or CABG between 1988
and 1991. Stents and IIb/IIIa inhibitors were not utilized. Since patients in BARI with
diabetes mellitus had greater survival with CABG, separate analyses of patients without
diabetes were performed.
RESULTS Seven-year survival among patients with three-vessel disease undergoing PTCA and CABG
(n 754) was 79% versus 84% (p 0.06), respectively, and 85% versus 87% (p 0.36) when
only non-diabetics (n 592) were analyzed. In patients with three-vessel disease and reduced
LV function (ejection fraction 50%), seven-year survival was 70% versus 74% (p  0.6) in
all PTCA and CABG patients (n  176), and 82% versus 73% (p  0.29) among
non-diabetic patients (n  124). Seven-year survival was 87% versus 84% (p  0.9) in all
PTCA and CABG patients (including diabetics) with two-vessel disease involving the
proximal LAD (n  352), and 78% versus 71% (p  0.7) in patients with two-vessel disease
involving the proximal LAD with reduced LV function (n  72).
CONCLUSION In high–risk anatomic subsets in which survival is prolonged by CABG versus medical
therapy, revascularization by PTCA and CABG yielded equivalent survival over seven years.
(J Am Coll Cardiol 2001;38:1440–9) © 2001 by the American College of Cardiology
In several clinical trials, revascularization by coronary artery
bypass graft (CABG) surgery increased survival compared
with medical therapy in patients with three-vessel disease
and two-vessel disease when the proximal left anterior
descending artery (LAD) was involved, with or without left
ventricular (LV) dysfunction (1–6). Although percutaneous
transluminal coronary angioplasty (PTCA) was originally
utilized for patients with symptomatic single-vessel disease,
multiple clinical trials have found that long-term survival
among patients with multivessel disease (MVD) undergoing
PTCA is similar to that of patients treated surgically (7–12).
The largest such trial was the Bypass Angioplasty Revascu-
larization Investigation (BARI), an international random-
ized clinical trial supported by the National Heart, Lung,
and Blood Institute in which an initial strategy of PTCA or
CABG was compared among patients with symptomatic
MVD (12). Five-year survival among patients assigned to
PTCA was similar to that of patients assigned to CABG
(12). However, it is unclear whether PTCA is associated
with similar survival to CABG specifically in those ana-
tomic subsets in which randomized trials have shown
CABG to prolong survival compared with medical therapy.
Accordingly, we performed this study specifically analyz-
ing anatomic subsets in BARI nominally identical to those
in which a benefit from CABG relative to medical therapy
From the *Division of Cardiovascular Disease, Mayo Clinic, Rochester, Minnesota;
†University of Pittsburgh, Pittsburgh, Pennsylvania; ‡NYU Medical Center, New
York, New York; §Boston Medical Center, Boston, Massachusetts; University of
Chicago, Chicago, Illinois; ¶Seattle Veterans Administration Hospital, Seattle,
Washington; #University of Massachusetts Medical Center, Worcester, Massachu-
setts; and **Brown University/Rhode Island Hospital, Providence, Rhode Island.
Financial support for this study was provided by National Heart, Lung and Blood
Institute grants HL38493, HL38504, HL38509, HL38512, HL38514-6, HL38518,
HL38524-5, HL38528, HL38532, HL38556, HL38610, HL38642 and HL42145.
Manuscript received November 15, 2000; revised manuscript received June 22,
2001, accepted July 16, 2001.
Journal of the American College of Cardiology Vol. 38, No. 5, 2001
© 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00
Published by Elsevier Science Inc. PII S0735-1097(01)01571-6
was reported (1–6). Such subgroup analyses were specified
by the BARI design.
METHODS
The BARI trial protocol, including a detailed description of
the study aims, patient selection, exclusion criteria, proce-
dure guidelines, definitions and administrative structure, has
been published (13–18). Briefly, patients were eligible for
BARI if they had MVD with either severe angina or
objective evidence of marked myocardial ischemia requiring
revascularization and were suitable for both PTCA and
CABG. Between August 1988 and August 1991, 1,829
patients (12% of patients screened) from 18 clinical centers
were enrolled in the randomized trial. Patients were fol-
lowed up an average of 7.7 years until September 15, 1997,
when 77% had seven years of follow-up (and 97% had vital
status ascertained). Although the primary end point of
BARI was survival at five years, a subsequent analysis
revealed greater survival at seven years among CABG
patients (84.4% vs. 80.9%, p  0.043). The difference in
survival was entirely due to diabetic patients. Diabetic
patients in BARI, defined as patients receiving insulin or
oral hypoglycemic therapy, had greater survival with CABG
than PTCA (76.4% vs. 55.7%, p  0.0011); non-diabetic
patients had similar seven-year survival (86.4% vs. 86.8%,
p  0.72%). In the current study, subgroup analyses, most
of which were prespecified by protocol, were carried out on
patients with and without diabetes who had three-vessel
disease and two-vessel disease including the proximal LAD,
with and without LV dysfunction. Left ventricular dysfunc-
tion was defined as an LV ejection fraction (EF) 50% (or,
if the LVEF was missing, as the sum of five regional wall
motion scores 10).
Initial revascularization procedures. A central laboratory
using a quantitative angiographic coding system (18) ana-
lyzed LV and coronary angiographic findings. Successful
dilatation, defined as a reduction in luminal diameter
narrowing 20%, a final lumen diameter narrowing 50%,
and Thrombolysis In Myocardial Infarction (TIMI) grade 3
flow, was achieved in all lesions treated by PTCA in 60.3%
of patients who underwent PTCA. The 891 patients who
received their treatment had 2,252 lesions attempted. The
success rate for dilation of each lesion was 79.7%.
STATISTICS. Results are summarized as means and medians
for continuous variables and percentages for categorical
variables. Within each subgroup defined by vessel disease,
EF and presence of proximal LAD disease, treatment
differences (CABG vs. PTCA) were analyzed by Wilcoxon
Rank Sum test for continuous variables and chi-square
testing for categorical variables. Seven-year event rates were
estimated from life table analyses using the product limit
method. Cox proportional hazards regression models were
used to obtain adjusted relative risks and analyze interac-
tions between treatment and key variables regarding seven-
year survival.
RESULTS
Baseline characteristics. The baseline characteristics of all
patients, and patients without diabetes, with three-vessel
disease, three-vessel disease with reduced ventricular func-
tion, two-vessel disease (including the proximal LAD) and
two-vessel disease (including the proximal LAD) with
reduced ventricular function are presented in Table 1
stratified by treatment. In all of these subgroups, baseline
characteristics were comparable among patients randomly
assigned to PTCA and CABG.
The angiographic characteristics of patients in each of the
subsets are presented in Table 2. These characteristics were
also comparable between treatment groups.
Seven-year survival. Survival curves of patients with three-
vessel disease (n  754) are shown in Figure 1. An internal
mammary artery (IMA) was used in 86.1% of CABG
patients. The mean LVEF was 55.8  11.4% in the two
groups. There was a strong trend toward a lower survival
among the PTCA (n  378) vs. CABG (n  376) patients
(79% vs. 84%, p  0.06) at seven years. Survival curves of
patients with three-vessel disease and reduced ventricular
function are shown in Figure 2. The mean LVEF was 41 
6.4% in the PTCA and CABG groups; an IMA was used in
87.7% of CABG patients. Survival at seven years was similar
between PTCA (n  94) and CABG (n  82) patients
(70% vs. 74%, p  0.6).
When patients with diabetes are excluded from analysis,
the survival curves of non-diabetic patients with three-vessel
disease reveal no difference in survival between the PTCA
(n  302) and CABG (n  290) groups (85% vs. 87%, p 
0.36) at seven years (Fig. 3). Similarly, survival of non-
diabetic patients with three-vessel disease and reduced
ventricular function (n  124) was not statistically different
(82% vs. 73%, p 0.29) among PTCA and CABG patients
(Fig. 4).
Survival of all patients with two-vessel disease including
the proximal LAD (n  352) are shown in Figure 5. An
IMA was used in 86.3% of CABG patients; the mean
LVEF was 56.7  11.7% in the two groups. No survival
difference was seen between the PTCA (n  172) and
CABG (n  180) groups (87% vs. 84%, p  0.9) at seven
years, overall. Among patients with two-vessel disease
Abbreviations and Acronyms
BARI  Bypass Angioplasty Revascularization
Investigation
CABG coronary artery bypass graft
EF  ejection fraction
IMA  internal mammary artery
LAD  left anterior descending artery
LV  left ventricular
MVD  multivessel disease
PTCA  percutaneous transluminal coronary angioplasty
TIMI  Thrombolysis In Myocardial Infarction
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Table 1. Baseline Clinical Characteristics of Patients in the Different Anatomic Subgroups of the Study Population by Assigned Treatment
Characteristic
3VD 3VD No DM 3VD LVEF <50% 2VD pLAD 2VD pLAD LVEF <50%
CABG
(n  376)
PTCA
(n  378)
CABG
(n  290)
PTCA
(n  302)
CABG
(n  82)
PTCA
(n  94)
CABG
(n  180)
PTCA
(n  172)
CABG
(n  35)
PTCA
(n  37)
Age, yr
Mean 61.3 62.4 61.3 62.2 59.2† 63.2 61.7 60.7 60.8 60.1
Median 62.3 62.7 62.4 62.5 59.6† 63.6 63.0 60.9 63.9 60.2
Age 65, % 39 39 40 37 29 43 41 34 43 27
Age 75, % 5 8 5 7 4 7 8 6 3 3
Female, % 26 25 22 22 26 23 27 27 26 22
Treated DM, % 23 20 0 0 32 28 19 18 31 41
Hypertension, % 55 50 49 45 48 44 45 45 51 38
Hypercholesterolemia, % 45 44 44 43 46 41 43 36 45 34
History of CHF, % 9 9 7 6 15 22 8 9 26 22
Prior MI, % 60 54 59 55 84 75 50 56 79 86
Angina at baseline
Unstable or with MI, % 73 70 71 71 71 77 67 71 74 72
CSC class II/IV, % 14 16 14 15 14 10 17 13 15 14
CSC class I/II, % 13 14 14 14 15 13 16 16 12 14
Prior smoking, % 68 69 70 72 71 68 65 70 74 76
Current smoker, % 22 23 24 25 28 28 23 27 29 30
BMI 30, % 32 26 27 22 33 26 33 29 34 35
COPD, % 5 7 5 7 5 9 3 5 9 3
PVD, %
Cerebrovascular/TIA, % 7 8 6 7 5* 14 5 8 3 5
Other atherosclerosis, % 18 19 15 18 18 20 13 14 15 11
Carotid disease, % 74 79 77 76 61† 81 82† 70 86† 51
Creatinine 1.5 mg/dl, % 3 5 2 3 1 5 1 0 3 0
*p  0.05; †p  0.01.
BMI  body mass index; CABG  coronary artery bypass graft; CHF  congestive heart failure; COPD  chronic obstructive pulmonary lung disease; CSC  Canadian Society Classification; DM  diabetes mellitus; LVEF 
left ventricular ejection fraction; MI  myocardial infarction; pLAD  proximal left anterior descending artery involvement; PTCA  percutaneous transluminal coronary angioplasty; PVD  peripheral vascular disease; TIA  transient
ischemic attack; VD  vessels diseased.
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Table 2. Angiographic Characteristics of Patients With Three-Vessel Disease by Assigned Treatment
Characteristic
3VD 3VD No DM 3VD LVEF <50% 2VD pLAD 2VD pLAD LVEF <50%
CABG
(n  376)
PTCA
(n  378)
CABG
(n  290)
PTCA
(n  302)
CABG
(n  82)
PTCA
(n  94)
CABG
(n  180)
PTCA
(n  172)
CABG
(n  35)
PTCA
(n  37)
Vessels diseased
Mean 3.0 3.0 3.0 3.0 3.0 3.0 2.0 2.0 2.0 2.0
Median 3.0 3.0 3.0 3.0 3.0 3.0 2.0 2.0 2.0 2.0
Proximal LAD lesions
Mean 0.7 0.7 0.6 0.7 0.6 0.7 1.2 1.2 1.2 1.2
Median 1 1 1 1 1 1 1 1 1 1
No. of significant proximal LAD lesions
Mean 0.4 0.4 0.4 0.4 0.4 0.4 1.1 1.0 1.0 1.0
Median 0 0 0 0 0 0 1 1 1 1
Frequency of significant proximal LAD disease 42% 39% 40% 40% 43% 40% 100% 100% 100% 100%
Any proximal LAD disease 57% 55% 54% 55% 56% 55% 100% 100% 100% 100%
Total No. of lesions
Mean 7.7 7.8 7.5 7.7 7.8 7.7 6.1 6.1 6.4 5.9
Median 7 8 7 7 8 7 6 6 7 6
No. of significant lesions
Mean 4.3 4.4 4.2 4.3 4.5 4.5 2.9 3.0 2.9 3.0
Median 4 4 4 4 4 4 3 3 3 3
3 significant lesions 99% 97% 99% 98% 100% 98% 57% 56% 54% 62%
Any class C lesions 49% 48% 50% 49% 65% 59% 33% 31% 49% 38%
MJI  66 71% 69% 73% 67% 78% 79% 31%* 47% 37% 38%
Abnormal LV function 22% 26% 20% 23% 100% 100% 20% 22% 100% 100%
Any major ECG abnormality 48% 46% 46% 45% 72% 70% 39% 49% 66% 73%
*p  0.01.
ECG  electrocardiographic; MJI  myocardial jeopardy index; Other abbreviations as in Table 1.
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including the proximal LAD and reduced ventricular func-
tion (n  72), the mean LVEF was 40.0  6.0%, and an
IMA was used in 74.3% of CABG patients. There was no
survival difference between the PTCA (n 37) and CABG
(n  35) groups (78% vs. 71%, p  0.7) (Fig. 6). If only
non-diabetic patients with two-vessel disease including the
proximal LAD are analyzed (n  287), seven-year survival
was better in the PTCA patients compared with the CABG
patients (93% vs. 86%, p  0.27), although the difference
was not statistically significant (Fig. 7). Seven-year survival
among non-diabetic patients with two-vessel disease includ-
ing the proximal LAD and reduced ventricular function
tended to be greater among patients treated with PTCA
(90% vs. 67%, p  0.13), although only 46 such patients
were enrolled in BARI (Fig. 8).
Multivariate analysis. A Cox regression model revealed
that the choice of treatment (PTCA or CABG) was not
significantly different for patients with two- versus three-
vessel disease in terms of survival at seven years. Similarly,
there was no interaction between choice of treatment and
the presence of normal and abnormal LV function in terms
of survival at seven years.
Subsequent revascularization procedures. In BARI, among
the 915 randomized patients assigned to initial PTCA, 215
patients (23.5%) underwent one or more subsequent PTCA
procedures, 197 patients (21.5%) underwent CABG, and an
additional 113 patients (12.4%) underwent both subsequent
PTCA and CABG during the seven-year follow-up period.
Among the 914 patients assigned to initial CABG, nine
patients (1.0%) underwent a subsequent CABG procedure,
Figure 1. Survival curves of patients with three-vessel disease in the Bypass Angioplasty Revascularization Investigation undergoing percutaneous
transluminal coronary angioplasty (PTCA) and coronary artery bypass graft (CABG).
Figure 2. Survival curves of patients with three-vessel disease and reduced ventricular function undergoing percutaneous transluminal coronary angioplasty
(PTCA) and coronary artery bypass graft (CABG) in the Bypass Angioplasty Revascularization Investigation.
1444 Berger et al. JACC Vol. 38, No. 5, 2001
PTCA in BARI and Survival November 1, 2001:1440–9
91 patients (10.0%) underwent one or more PTCA, and an
additional seven patients (0.8%) underwent both CABG
and PTCA during the seven-year follow-up period.
DISCUSSION
Coronary artery bypass graft has been shown to increase
survival compared with medical therapy in patients with
three-vessel coronary artery disease and two-vessel disease
when the proximal LAD was involved, with or without LV
dysfunction (1–6). Cardiologists may therefore be reluctant
to recommend PTCA for such patients, even when PTCA
would be an option for revascularization. The purpose of the
analyses reported was to determine whether such reluctance
is justified.
Overall, the BARI trial, which compared an initial
strategy of PTCA or CABG (12) in patients with MVD,
did not find a difference in survival at five years. At seven
years, survival was greater among patients treated with
CABG (19). The BARI patients with diabetes mellitus who
underwent PTCA as an initial revascularization strategy had
a significantly higher five- and seven-year mortality compared
with those who underwent CABG if IMA grafts were utilized
(12,19). No difference in five- or seven-year survival was seen
between PTCA and CABG among non-diabetic patients.
Although the conclusion from the BARI investigators
indicating that CABG is the preferred initial revasculariza-
tion strategy for patients with diabetes has been met with
controversy, the magnitude of the difference in survival and
consistency with other trials suggests CABG is the pre-
ferred therapy for diabetic patients with three-vessel disease,
Figure 3. Survival curves of nondiabetic patients with three-vessel disease reveal no difference in survival between the percutaneous transluminal coronary
angioplasty (PTCA) and coronary artery bypass graft (CABG) groups at seven years.
Figure 4. Survival of non-diabetic patients with three-vessel disease and reduced ventricular function. CABG  coronary artery bypass graft; PTCA 
percutaneous transluminal coronary angioplasty.
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particularly those diabetic patients with diffuse disease in
whom a larger number of lesions require treatment. In the
BARI registry of clinically and angiographically eligible
patients who were not randomized, the outcome among
diabetic patients treated with PTCA was similar to that of
diabetic patients treated surgically (20). This is undoubtedly
because diabetic patients in the BARI registry with the most
extensive disease were treated surgically.
In our current analyses, there were no significant differ-
ences in seven-year survival between patients initially treated
with PTCA or CABG in any of the high-risk anatomic
subgroups analyzed. However, the trend toward greater
survival among patients with three-vessel disease who un-
derwent CABG undoubtedly represents a true benefit of
surgery among diabetic patients with three-vessel disease
that did not reach statistical significance, because of the
small sample size. When diabetic patients with three-vessel
disease were excluded from subsequent analyses, survival
with PTCA and CABG was similar among non-diabetic
patients. Conclusions from these analyses are consistent
with the main conclusion by the BARI investigators that
survival among patients assigned to an initial strategy of
PTCA was similar to that of patients treated with CABG,
except in diabetic patients (12). Analyses of patients with
and without diabetes with two-vessel disease including the
proximal LAD revealed similar survival rates at seven years
among patients initially treated with PTCA and CABG,
whether or not LV dysfunction was present. When diabetics
were excluded from analysis, seven-year survival among
patients with two-vessel disease including the proximal
LAD with or without reduced ventricular function revealed
a trend favoring PTCA.
Figure 5. Survival of all patients with two-vessel disease including the proximal left anterior descending artery. Abbreviations as in Figure 4.
Figure 6. Survival of all patients with two-vessel disease including the proximal left anterior descending artery and reduced ventricular function.
Abbreviations as in Figure 4.
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Implications for comparisons between PTCA and med-
ical therapy. If CABG prolongs survival compared with
medical therapy in certain anatomic subgroups, and PTCA
has a similar survival to CABG in several of those anatomic
subgroups, one might infer that PTCA may also provide a
survival advantage compared with patients treated medi-
cally. However, when examining trials comparing PTCA
versus CABG in patients with MVD, it must be remem-
bered that enrollment in the trials was limited to patients
whose coronary disease is amenable to both techniques. In
BARI, only 33% of patients with MVD who were clinically
eligible for BARI were amenable to PTCA, whereas 93% of
patients with MVD were amenable to CABG (16). In
general, unsuitable candidates for PTCA had more diffuse
and severe coronary disease, more frequently had occluded
vessels and ostial lesions and worse LV function (16).
In addition, since the trials comparing medical therapy
with CABG were performed, CABG has improved a great
deal. The left IMA was used in approximately 15% of
patients in those early randomized trials; it was utilized in
83% of CABG procedures in BARI and was associated with
improved survival and event-free survival following CABG
(13). However, medical therapy has also markedly im-
proved; thus, it is possible that CABG would no longer be
superior to medical therapy in these subgroups.
Finally, all of the analyses of high-risk patients included
too few patients to provide statistical certainty that there
was no significant difference in mortality between PTCA
and CABG. Based on the observed seven-year mortality in
the CABG group in each of the anatomic subsets, appro-
priately sized samples would require (with a beta of 0.8 and
alpha of 0.05) between 7,408 and 16,080 patients to be
Figure 7. Survival of non-diabetic patients with two-vessel disease including the proximal left anterior descending artery. Abbreviations as in Figure 4.
Figure 8. Survival of non-diabetic patients with two-vessel disease including the proximal left anterior descending artery and reduced ventricular function.
Abbreviations as in Figure 4.
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sufficiently powered to detect a relative 10% increase in
mortality in the PTCA arm compared with the CABG arm.
However, the 95% confidence intervals for the observed
survival seen with PTCA in BARI (Table 3) reveal that the
lower estimated survival with PTCA in most of these
anatomic subsets is equal to or greater than the actual
survival seen with CABG in BARI. Therefore, it is unlikely
that survival after PTCA would be significantly lower than
survival after CABG, had appropriately sized samples been
available for analysis. It should be remembered that the
largest study comparing surgical and medical therapy upon
which the survival benefits of CABG were established, the
Coronary Artery Surgery Study (n  780), was only slightly
larger than the largest subset of patients analyzed in the
current study, patients with three-vessel disease (n  754),
and smaller than the total number of patients analyzed in
the current study (n  1,829). For all these reasons, BARI
should not be considered to provide evidence about the
relative survival benefit of PTCA versus medical manage-
ment.
Recent advances in percutaneous revascularization. The
advances and refinements to PTCA affect not only the
frequency of a repeat revascularization procedure but also
mortality (21). A lower mortality has been found among
patients treated with both stents and the IIb/IIIa inhibitor
abciximab versus balloon angioplasty (even if abciximab was
used) among more than 2,400 patients enrolled in the
EPISTENT trial (22). The benefit of a stent and abciximab
was greatest among patients with diabetes mellitus (22).
Whether the outcome of diabetic (and other) patients would
have been improved had stents and these potent antiplatelet
agents been widely used, although likely, remains specula-
tive. Further studies are required to clarify the role of stents
and platelet glycoprotein IIb/IIIa inhibitors in diabetic
patients with MVD.
CONCLUSIONS
Data from the BARI trial show no difference in seven-year
survival between an initial strategy of PTCA or CABG
among non-diabetic patients with three-vessel, and among
all patients with two-vessel disease involving the proximal
LAD, amenable to both procedures. Although such patients
have been shown to live longer when treated with CABG
versus medical therapy, these data provide evidence that
PTCA may be offered to such patients as an initial revas-
cularization without compromising their seven-year sur-
vival.
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